Cross-Sector entity
Biogen is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Biogen is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Skyclarys (omaveloxolone), all published on August 3, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Skyclarys (omaveloxolone). Shared-story counts are live from our verified record — not editorial picks.
High Court grants permission for judicial review
Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
NCPE pharmacoeconomic evaluation completed
The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
HSE reimbursement application filed
Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
European market authorisation
The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
Diagnosis with Friedreich's ataxia
Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.
Biogen’s orphan drug for Friedreich’s ataxia, approved by the EMA since February 2024, remains mired in Irish reimbursement ambiguity, prompting a patient’s judicial review and highlighting the EU’s fragmented market access for novel therapies.
Emily Felix, 28, launches judicial review against the HSE for failing to decide on funding for Biogen's Friedreich's ataxia drug for nearly two years, despite EMA approval and availability across a dozen EU nations.
A woman with Friedreich’s ataxia sues the HSE over an unacceptably prolonged reimbursement decision for omaveloxolone, a treatment that could slow her decline and that is already standard care in 12 other European countries.
Source: roscommonherald.ie · laois-nationalist.ie
